Pinnbrook Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Pinnbrook Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-96,851	Closed	-$3.02M	–	110
2025 Q4	$3.02M	Buy	96,851 +93,885	+3,165%	+$2.31M	0.42%	70
2025 Q3	$59.9K	Buy	+2,966	New	+$52.1K	0.01%	139
2025 Q1	–	Sell	-225,320	Closed	-$4.97M	–	111
2024 Q4	$4.97M	Buy	+225,320	New	+$4.1M	0.49%	44
2024 Q3	–	Sell	-470,554	Closed	-$7.65M	–	100
2024 Q2	$7.65M	Buy	470,554 +8,854	+2%	+$136K	1.61%	22
2024 Q1	$6.51M	Buy	+461,700	New	+$5.82M	0.55%	62

Other funds holding TEVA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Pinnbrook Capital Management's TEVA Position: Q1 2026 in Review

Pinnbrook Capital Management sold out of Teva Pharmaceuticals (TEVA) in Q1 2026, closing a stake of 96,851 shares — an estimated $3.02M sold.

Pinnbrook Capital Management first reported a position in TEVA in Q1 2024 and held it in 5 quarters. The position peaked at $7.65M in Q2 2024. 650 funds tracked by Wall St. Rank hold TEVA as of Q1 2026.

Pinnbrook Capital Management reported no remaining Teva Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Pinnbrook Capital Management sold 96,851 Teva Pharmaceuticals shares in Q1 2026, an estimated $3.02M.
Pinnbrook Capital Management first reported a position in Teva Pharmaceuticals in Q1 2024 and held it in 5 quarters.
Pinnbrook Capital Management's Teva Pharmaceuticals position peaked at $7.65M in Q2 2024.
650 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2026.

Based on Pinnbrook Capital Management's 13F filing for Q1 2026, filed 14 May 2026.